Skip to main content

Immune Response BioPharma, Inc.

Home
Drug Discovery
Press Releases
Investor Relations
Royalties
Stock Information
Executive Team
Scientific Board
Clinical Trials
REMUNE Vaccine
REMUNE Rx Co-pay Card
REMUNE FULL PRESCRIBING
REMUNEX Vaccine
Remune Pediatric
RemuneVax Vaccine
NeuroVax Vaccine
NeurOral
RAVAX Vaccine
RAVAX II Vaccine
Zorcell Vaccine
DermaVax
Immunereszumab
Sepsicillin
Rare Diseases
Alliances
Vaccines Direct
Partnering
Bio Defense
Immune Response Hospital
Orchestra Therapeutics
Research Donations
About Us
Corporate Filings
Corporate ByLaws
Transfer Agent
Employment
Events
Webcast
Contact Us
Email Alerts
Member Login
Site Map

Immune Response BioPharma, Inc. TM  © 2010-2018

The Vaccine Development Company for the 21st Century & Beyond

an Orphan Drug Manufacturer 

Home Page
undefinedundefined

Auto-Immune & Infectious Disease Drug Discovery & Research
Mission to Become the World Leader In Saving Lives & Vaccine Technology

NeuroVax TM First in Class MS Vaccine FDA FastTrack
SPMS & Orphan Pediatric Designations   

REMUNE TM  First in Class Rescue HIV/AIDS Vaccine
 & FDA Orphan Pediatric Designation 


IRBP Files New 2nd REMUNE BLA with FDA for FDA Orphan Pediatric Designated Indication 03/31/2017

IRBP Files Amended Remune BLA with FDA 08/06/2016

& FDA Fast Track Designation for SPMS



 



Immune Response BioPharma, Inc. TM
 All Rights Reserved
Superior Science! 
Remune: the Most Tested HIV Vaccine in History 
& First FDA Filed Vaccine for Approval & New Second Vaccine Product FDA Orphan Pediatric Indication FDA BLA filing

                                                                           
                                             

Copyright © 2010-2018  www.immuneresponse.net